Hepatitis C seroprevalence and its association with injecting drug use among people who use drugs in the West Bank, Palestine: a retrospective cross-sectional study

BACKGROUND: People who use drugs (PWUD) are at increased risk of blood-borne viral infections. Evidence on hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) among PWUD in Palestine is limited. This study determined the seroprevalence of HCV, HBV, and HIV among PWUD attending governmental substance use disorder (SUD) treatment centers in the West Bank. METHODS: This retrospective cross-sectional study included 397 PWUD in SUD treatment centers in the West Bank during 2019-2023. Serological results for anti-HCV, HBsAg, and anti-HIV were obtained from routine clinical records. Crude and adjusted prevalence ratios (PRs) for the association between injecting drug use and anti-HCV seropositivity were estimated using modified Poisson regression. RESULTS: HCV seroprevalence was 23.0%, HBsAg prevalence was 2.0%, and no HIV was detected. HCV seroprevalence was 55.4% among injecting versus 6.7% among non-injecting users. After adjustment for age, education, employment status, and previous treatment attempts, injecting drug use remained strongly associated with HCV seropositivity (adjusted PR = 6.43, 95% CI 3.82-10.82). HCV prevalence increased with longer duration of drug use (p for trend <0.001), and varied significantly across governorates. CONCLUSIONS: HCV is the predominant infection among PWUD receiving SUD treatment in the West Bank, whereas HBV prevalence was low and HIV was not detected. Injecting drug use was strongly associated with HCV seropositivity, and prevalence increased with longer duration of drug use. Integrating HCV screening, RNA testing, antiviral treatment, and harm-reduction policies into SUD services is essential to achieve the WHO 2030 hepatitis elimination targets.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Policy
Published
2026-11-18
DOI
https://doi.org/10.1016/j.drugpo.2026.105607
Primary Topic
Hepatitis C virus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatitis C seroprevalence and its association with injecting drug use among people who use drugs in the West Bank, Palestine: a retrospective cross-sectional study

Asad Ramlawi, Radwan Qasrawi, Ghada Issa, Razan Abu Ghoush et al.
3 links
International Journal of Drug Policy
Hepatitis C virus research
article

Hepatitis C seroprevalence and its association with injecting drug use among people who use drugs in the West Bank, Palestine: a retrospective cross-sectional study

Asad Ramlawi, Radwan Qasrawi, Ghada Issa, Razan Abu Ghoush, Maria Kokali, Abeer Habash
article en

Abstract

BACKGROUND: People who use drugs (PWUD) are at increased risk of blood-borne viral infections. Evidence on hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) among PWUD in Palestine is limited. This study determined the seroprevalence of HCV, HBV, and HIV among PWUD attending governmental substance use disorder (SUD) treatment centers in the West Bank. METHODS: This retrospective cross-sectional study included 397 PWUD in SUD treatment centers in the West Bank during 2019-2023. Serological results for anti-HCV, HBsAg, and anti-HIV were obtained from routine clinical records. Crude and adjusted prevalence ratios (PRs) for the association between injecting drug use and anti-HCV seropositivity were estimated using modified Poisson regression. RESULTS: HCV seroprevalence was 23.0%, HBsAg prevalence was 2.0%, and no HIV was detected. HCV seroprevalence was 55.4% among injecting versus 6.7% among non-injecting users. After adjustment for age, education, employment status, and previous treatment attempts, injecting drug use remained strongly associated with HCV seropositivity (adjusted PR = 6.43, 95% CI 3.82-10.82). HCV prevalence increased with longer duration of drug use (p for trend <0.001), and varied significantly across governorates. CONCLUSIONS: HCV is the predominant infection among PWUD receiving SUD treatment in the West Bank, whereas HBV prevalence was low and HIV was not detected. Injecting drug use was strongly associated with HCV seropositivity, and prevalence increased with longer duration of drug use. Integrating HCV screening, RNA testing, antiviral treatment, and harm-reduction policies into SUD services is essential to achieve the WHO 2030 hepatitis elimination targets.

International Journal of Drug PolicyVol. 159
Bethlehem University (PS), Al-Quds University (PS), Istinye University (TR)
Good health and well-being
Hepatitis C virus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon